RegCell is pioneering advancements in immunotherapy, specifically targeting autoimmune diseases through innovative immune regulation techniques. The company is developing a pipeline utilizing S/F-iTreg technologies, which focus on creating stable and functional antigen-specific regulatory T cells (Tregs) from effector T cells. This approach aims to treat a wide range of autoimmune and inflammatory diseases, as well as improve outcomes in transplantation scenarios. RegCell's commitment to excellence is reflected in their robust manufacturing operations, which are built on decades of process development and innovation, ensuring high efficiency in the generation of these specialized Tregs.

The company is currently in the pre-clinical stage with its lead product, RegPD-101, and is strategically selecting specific target diseases for clinical trials. These targets are chosen based on criteria such as the presence of known antigens, the ability to quickly confirm treatment efficacy, and the high market need for solutions to severe and refractory conditions. RegCell is also focused on R&D collaborations, leveraging its proprietary S/F-iTreg technologies to enhance the stability and functionality of partner pipelines in cell therapy. Their established protocols for the induction of highly functional Tregs from both mouse and human cells further underscore their innovative approach to advancing cell-based therapies in the field of immunology.

Japan

Based on the discovery by our Founder, Professor Shimon Sakaguchi, we are developing stable, functional-induced Tregs that are antigen-specific (S/F-iTregs). Our S/F-iTregs address the limitations of earlier attempts to create therapeutic Tregs and competitive advantages over CAR-Treg approaches.

RegCell

Company Details